Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records
Claim this profileCapability statement (.md)

NUVOX PHARMA, L.L.C.

UEIWHNYG96UDLJ8CAGE51P42NAICS541713
  • SAM expiring
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$0
Awards on record
0
Contract vehicles
0
Verified credentials
0

SAM.gov registration expires in 55 days

NUVOX PHARMA, L.L.C.’s registration expires on Jan 7, 2027. Renewal can take weeks; confirm it stays active through proposal submission and award.

View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI

About NUVOX PHARMA, L.L.C.

NUVOX PHARMA, L.L.C. is a SAM.gov-registered entity based in TUCSON, AZ 85719-6803. UEI WHNYG96UDLJ8; CAGE 51P42; primary NAICS 541713. Compliance posture not provided. SAM registration expires in 55 days.
Headquarters
TUCSON, AZ 85719-6803

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIWHNYG96UDLJ8
  • CAGE51P42

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.
Is this your company? Claim it

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.
Is this your company? Claim it

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

Past performance

Recompete RadarLearn more about past performance

No federal prime awards on record

USAspending shows no prime awards for this UEI in the last 36 months. Subcontract work does not appear here.
Claim this profile

Contract vehicles

Learn more about GWACs, IDIQs and contract vehicles

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Browse vehicle holders

Proven teaming graph

Learn more about sub-award reporting (FSRS)
Who NUVOX PHARMA, L.L.C. has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.
See where agencies spend

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more about SBIR/STTR Phase IIIAbout SBIR/STTR (opens in a new tab)
Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
12 awards
Total awarded
$8,518,151
By phase
  • SBIR Phase I: 4
  • SBIR Phase II: 4
  • STTR Phase I: 4
By agency
  • Department of Health and Human Services: 12
Active projects
1 project
Projects whose contract end date is today or later.
Phase II ending within 12 months
1 project
Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
By year
  • 2025: 1
  • 2023: 1
  • 2021: 1
  • 2018: 2
  • 2017: 2
  • 2016: 3
  • 2014: 1
  • 2010: 1

Awards (most recent first)

  • Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $919,366

    Sep 22, 2025 – Aug 31, 2027

    • Active
    • Ends Aug 2027

    Solicitation PA24-246 (2024) · Topic 102

  • Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $900,552

    Apr 15, 2023 – Mar 31, 2026

    Solicitation NS22-033 (2022) · Topic NINDS

  • NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $478,050

    Sep 15, 2021 – Aug 31, 2022

    Solicitation PA20-265 (2020) · Topic 106 · Research partner: UNIVERSITY OF ARIZONA

  • Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $1,996,751

    Jul 12, 2018 – Jun 30, 2020

    Solicitation PA17-302 (2017) · Topic 102

  • Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $143,988

    Dec 1, 2017 – May 31, 2019

    Solicitation PA16-302 (2016) · Topic 101

  • Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $2,492,571

    Sep 12, 2017 – Feb 29, 2024

    Solicitation CA16-008 (2016) · Topic 102

  • Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $317,743

    Apr 1, 2017 – Sep 30, 2018

    Solicitation PA16-302 (2016) · Topic NHLBI

  • B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $298,820

    Sep 19, 2016 – Aug 31, 2018

    Solicitation PA15-270 (2015) · Topic 102

  • Targeted and Non-targeted Microbubbles for Pediatric Applications

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $243,164

    Sep 1, 2016 – Feb 28, 2018

    Solicitation PA15-270 (2015) · Topic NICHD

  • Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $297,786

    Mar 15, 2016 – Feb 28, 2018

    Solicitation PA14-072 (2014) · Topic 394

  • IGF::OT::IGF SBIR Topic 85 To support the development of target specific molecular imaging agents in combination with existing imaging modalities to detect high risk atherosclerotic plaque.

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $225,000

    Solicitation year 2014 · Topic NHLBI · Research partner: Stub

  • Development of Novel Sensitizer to Improve Response of Hypoxic Tumors to Radiatio

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $204,360

    Solicitation PHS2010-2 (2010) · Topic NCI

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

FedRAMP offerings

Learn more about the FedRAMP Marketplace
Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.
Find FedRAMP-authorized companies

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Exclusions & screening

Exclusions about SAM.gov exclusionsScreening list about the Consolidated Screening List
Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026

GSA CALC+ rate benchmark

Learn more about GSA CALC+ labor rates
Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.
See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded

NAICS, PSC & socio-economic status

Learn more about NAICS size standards
Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 541713Research and Development in NanotechnologyPrimary

SAM.gov does not report this entity as small under any listed NAICS code.

Socio-economic status

No socio-economic certifications reported in SAM.gov.

Product & service codes (PSC)

No PSC codes reported.

Teaming preferences

Learn more about teaming agreements and joint ventures

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Is this your company? Claim it

Corporate hierarchy

Affiliation & size about affiliation and size
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.

  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with NUVOX PHARMA, L.L.C.?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.

Claim this profileCapability statement (.md)